Nippon India Pharma Fund - Direct Plan - Growth Plan
Nippon India Pharma Fund - Direct Plan - Growth Plan

Nippon India Pharma Fund - Direct Plan - Growth Plan

Compare
Equity
Direct
Sector - Healthcare

NAV: ₹ 322.8 as on 02-06-2023

Fund Performance
zero opening, trading, fund transfer fee
5935 people have invested ₹ 1.3Cr in Nippon India Pharma Fund - Direct Plan - Growth Plan in the last three months

Fund Insights

Insights icon

In the last 1 year, SBI Healthcare Opportunities Fund Direct Growth has given 17.88% return, outperforming Nippon India Pharma Fund - Direct Plan - Growth Plan by 5.66%

Insights icon

In the last 3 years, DSP Healthcare Fund Direct Growth has given 21.55% return, outperforming Nippon India Pharma Fund - Direct Plan - Growth Plan by 4.09% per annum

Insights icon

In the last 5 years, Mirae Asset Healthcare Fund Direct Growth has given 18.52% return, outperforming Nippon India Pharma Fund - Direct Plan - Growth Plan by 0.44% per annum

Insights icon

Over the last 1 month, Nippon India Pharma Fund - Direct Plan - Growth Plan has decreased expense ratio by 16.7% moving from 1.26 to 1.05

Insights icon

Nippon India Pharma Fund - Direct Plan - Growth Plan has one of the lowest expense ratio in the category (sector - healthcare). Its expense ratio is 1.05% which is lower than the category average expense ratio of 1.54%

Insights icon

Nippon India Pharma Fund - Direct Plan - Growth Plan with AUM at ₹4510.77Cr is among the largest funds in the sector - healthcare category

Insights icon

Over the last 6 months, Nippon India Pharma Fund - Direct Plan - Growth Plan has experienced a 5.7% drop in AUM moving from 4.78K Cr to 4.51K Cr

INDmoney Rank

Powered by IND quant engine
IND ranking is not available for this fund.

Pros

5Y returns in the top 25% of the category

3Y returns in the top 25% of the category

Among most bought funds within the category

Cons

No bad points found for this fund.

About the Fund

Nippon India Pharma Fund - Direct Plan - Growth Plan is an equity fund. This fund was started on 1 January, 2013. The fund is managed by Sailesh Raj Bhan, Akshay Sharma, Kinjal Desai. The fund could potentially beat inflation in the long-run.

Key Parameters

  1. Nippon India Pharma Fund - Direct Plan - Growth Plan has a NAV of ₹322.8 as on 02-06-2023.
  2. Nippon India Pharma Fund - Direct Plan - Growth Plan has ₹4511 Cr worth of assets under management (AUM) as on 30-04-2023 and is more than category average.
  3. The fund has an expense ratio 1.1.

Nippon India Pharma Fund - Direct Plan - Growth Plan Overview

Expense ratio
Expense ratio
1.05%
Benchmark
Benchmark
S&P BSE Healthcare PR
AUM
AUM
₹4511 Cr
Inception Date
Inception Date
1 January, 2013
Min Lumpsum/SIP
Min Lumpsum/SIP
₹5000/₹100
Exit Load
Exit Load
1%
Lock In
Lock In
No Lock-in
TurnOver
TurnOver
38.42%

Fund Distribution as on (30-Apr-23)

  • Equity 96.8%

  • Debt & Cash 3.2%

Size breakup

Large cap
41.5%
Mid cap
32.3%
Small cap
22.6%

Sector Allocation

Apr'23

Mar'23

Feb'23

Health

100%

Top Holdings of Nippon India Pharma Fund - Direct Plan - Growth Plan as on (31-May-23)

  • Equity

Equity Holdings28

Nippon India Pharma Fund - Direct Plan - Growth Plan: Monthly Changes Updates

All changes are between Feb'23 and Apr'23

Fund Performance

Apr'23
Mar'23
Feb'23
Fund Returns
1.51%
1.51%
-3.12%
Nifty 500
-0.73%
-0.73%
-2.22%
  • This fund’s returns stands at 1.51% whereas the fund’s underlying benchmark Nifty 500 returns stands at -0.73% as on Apr'23
  • This fund outperformed Nifty 500 by 2.24% in Apr'23

AUM Change

Parameters
Apr'23
Mar'23
Feb'23
AUM
₹ 4.5K Cr
₹ 4.3K Cr
₹ 4.3K Cr
  • AUM of the fund stands at 4.5K Cr as of Apr'23
  • AUM increased by 206.3 Cr between Apr'23 and Mar'23

Fund Portfolio Changes

Gainers & Losers in Nippon India Pharma Fund - Direct Plan - Growth Plan portfolio as on (30-Apr-23)

Nippon India Pharma Fund - Direct Plan - Growth Plan Fund Manager

Sailesh Raj Bhan

Sailesh Raj Bhan

Fund Manager of Nippon India Pharma Fund - Direct Plan - Growth Plan, since 1 April 2005
Akshay Sharma

Akshay Sharma

Fund Manager of Nippon India Pharma Fund - Direct Plan - Growth Plan, since 1 December 2022
Kinjal Desai

Kinjal Desai

Fund Manager of Nippon India Pharma Fund - Direct Plan - Growth Plan, since 25 May 2018

Fund Highlights

Risk meter
pointer

Very High Risk

Investors understand that their principal will be at Very High Risk
About the fund

About the fund

This fund has delivered an average annual returns of 15.85% since inception which is more than its category average return of 15.5%
Fund Allocations

Fund Allocations

This fund has an allocation of 96.77% in Equity, 0% in Debt and 3.23% in Cash related instruments
AUM size ₹4511 Cr

AUM size ₹4511 Cr

This fund has AUM of ₹4511 Cr which is more than its category average of ₹ 1299 Cr
Expense Ratio 1.05%

Expense Ratio 1.05%

This fund has an expense ratio of 1.05% which is less than its category average expense ratio of 1.52%

Frequently Asked Questions

The current NAV of Nippon India Pharma Fund - Direct Plan - Growth Plan is ₹322.81 as on 02-Jun-2023.
Existing (Absolute + CAGR) as on 02-Jun-2023.
Nippon India Pharma Fund - Direct Plan - Growth Plan
Absolute Returns
CAGR Returns
1 Month Returns
4.65%
4.65%
6 Month Returns
1.63%
1.63%
1 Year Returns
12.22%
12.22%
3 Years Returns
62.07%
17.46%
5 Years Returns
129.55%
18.08%
With INDmoney, the process of investing is very simple and involves zero commission.
  • Click Buy on the fund name.
  • Input the amount you are looking to invest.
  • Select Lump Sum or SIP (Weekly, Monthly or Quarterly).
  • Select your bank account and proceed with Payment.
1.05% as on May 2023
₹4511 Cr as on May 2023
Sun Pharmaceuticals Industries Ltd(14.36%), Dr Reddy's Laboratories Ltd(7.1%), Lupin Ltd(6.93%), Cipla Ltd Shs Dematerialised(6.04%), Apollo Hospitals Enterprise Ltd(5.21%) as on May 2023
The alpha ratio for the Nippon India Pharma Fund - Direct Plan - Growth Plan for various period is as follows:
Fund Name
Alpha 1 Year
Alpha 3 Years
Alpha 5 Years
Nippon India Pharma Fund - Direct Plan - Growth Plan
2.89
1.87
4.22
As on May 2023
The alpha for Nippon India Pharma Fund - Direct Plan - Growth Plan is calculated against S&P BSE Healthcare PR. Higher alpha indicates that this fund has generated extra returns compared to the benchmark index. An alpha of 1.0 means the fund has outperformed its benchmark index by 1%.
The Beta ratio for the Nippon India Pharma Fund - Direct Plan - Growth Plan for various period is as follows:
Fund Name
Beta 1 Year
Beta 3 Years
Beta 5 Years
Nippon India Pharma Fund - Direct Plan - Growth Plan
0.87
0.93
0.89
As on May 2023
The Beta for Nippon India Pharma Fund - Direct Plan - Growth Plan is calculated with S&P BSE Healthcare PR. Beta tells the volatility of the mutual fund relative to its benchmark. If the beta of a mutual fund is more than 1, then the mutual fund is more volatile than its benchmark. If beta is less than 1, then the mutual fund is less volatile than the benchmark.
The sharpe ratio for the Nippon India Pharma Fund - Direct Plan - Growth Plan for various period is as follows:
Fund Name
Sharpe Ratio 1 Year
Sharpe Ratio 3 Years
Sharpe Ratio 5 Years
Nippon India Pharma Fund - Direct Plan - Growth Plan
0.33
0.81
0.7
As on May 2023
The sharpe ratio for Nippon India Pharma Fund - Direct Plan - Growth Plan is calculated with S&P BSE Healthcare PR. Sharpe ratio tells risk-adjusted-returns of the mutual fund. The higher a fund's Sharpe ratio, the better a fund's returns have been relative to the risk it has taken on.
The standard deviation for the Nippon India Pharma Fund - Direct Plan - Growth Plan for various period is as follows:
Fund Name
Standard Deviation 1 Year
Standard Deviation 3 Years
Standard Deviation 5 Years
Nippon India Pharma Fund - Direct Plan - Growth Plan
10.4
15.3
18.15
As on May 2023
Standard deviation tells the volatility of the returns of the mutual fund. The higher a fund's Standard deviation, the higher the volatility of the fund's returns.
Sortino ratio is 1.46 as on May 2023. Sortino ratio tells the downside risk-adjusted-returns of the mutual fund.
Information ratio is 0.42 as on May 2023. It tells the consistency of the fund in generating superior risk-adjusted performance
Sailesh Raj Bhan, Akshay Sharma, Kinjal Desai are the fund managers of Nippon India Pharma Fund - Direct Plan - Growth Plan
The Exit load of Nippon India Pharma Fund - Direct Plan - Growth Plan is 1%